Large B-cell lymphoma is a cancer that starts in white blood cells called B lymphocytes, which are part of your immune system. It is the most common type of non-Hodgkin lymphoma, and the most frequent form is called diffuse large B-cell lymphoma, or DLBCL. The word “diffuse” means the cancer cells spread throughout the affected tissue rather than clumping into distinct clusters. About 65% of people diagnosed with DLBCL survive at least five years, though outcomes vary widely depending on stage, age, and subtype.
How This Cancer Develops
B cells are immune cells that normally produce antibodies to fight infections. They mature in structures called germinal centers inside your lymph nodes. During this process, B cells undergo rapid genetic changes to fine-tune their antibody production. Sometimes those genetic changes go wrong, and a B cell begins growing uncontrollably instead of doing its normal job. That’s how large B-cell lymphoma begins.
Most cases arise on their own, without a prior blood disorder. But some develop when a slower-growing cancer transforms into something more aggressive. For example, a low-grade lymphoma like follicular lymphoma, or a condition called chronic lymphocytic leukemia, can sometimes evolve into DLBCL. When this happens, it’s called a transformation.
Molecular Subtypes
Not all DLBCL behaves the same way, because the cancer can arise from B cells at different stages of development. Gene profiling divides DLBCL into two major subtypes. The germinal center B-cell type (GCB) comes from B cells still inside the germinal center and tends to carry genetic changes in genes that control cell development there. The activated B-cell type (ABC) comes from B cells that have exited or are about to exit the germinal center, and it is driven largely by a signaling pathway that keeps the cancer cells alive when they should naturally die off.
These subtypes matter because they respond differently to treatment. The ABC subtype has historically been harder to treat than the GCB subtype, which is one reason doctors increasingly test for molecular subtype at diagnosis. There are also particularly aggressive forms called “double-hit” lymphomas, where cells carry rearrangements in two key genes (MYC along with BCL2 or BCL6). These cases require more intensive treatment.
Common Symptoms
The most noticeable sign is usually a rapidly growing, painless lump, most often in the neck, armpit, or groin. These lumps are swollen lymph nodes packed with cancer cells. Because DLBCL grows quickly, the swelling can appear over just a few weeks.
Beyond swollen nodes, doctors look for what are called “B symptoms,” a specific set of three warning signs:
- Unexplained fever not caused by an infection
- Drenching night sweats severe enough to soak through clothing or bedsheets
- Unintentional weight loss of more than 10% of body weight over six months
Having B symptoms generally signals a more advanced or aggressive disease and affects how doctors plan treatment. Other possible symptoms include fatigue, loss of appetite, and occasionally pain or pressure if enlarged nodes press on nearby organs.
How It Is Diagnosed
A diagnosis requires a biopsy, usually of a swollen lymph node. Pathologists examine the tissue under a microscope, looking for large cancerous B cells that are bigger than normal immune cells. To confirm the type, they test the tissue for specific proteins on the cell surface. DLBCL cells typically show positive markers for proteins called CD20 and CD79, which identify them as B cells. Additional markers like CD10, BCL2, and BCL6 help pin down the exact subtype and guide treatment choices.
After the biopsy confirms the diagnosis, imaging scans (usually a PET-CT scan) map where the cancer has spread. Blood tests check for elevated levels of an enzyme called LDH, which can indicate how fast the cancer is growing.
Staging
DLBCL is staged using a system that tracks how far the cancer has spread through the body’s lymphatic system:
- Stage I: Cancer is in a single lymph node region.
- Stage II: Cancer involves two or more lymph node regions, but all on the same side of the diaphragm (either above or below the muscle that separates chest from abdomen).
- Stage III: Cancer is found in lymph node regions on both sides of the diaphragm.
- Stage IV: Cancer has spread beyond the lymph nodes into organs like the bone marrow, liver, or lungs.
Each stage can also be labeled “A” (no B symptoms) or “B” (B symptoms present), which adds prognostic information.
Predicting Outcomes
Doctors use a tool called the International Prognostic Index (IPI) to estimate how a patient is likely to respond. It scores five factors: age (over or under 60), stage, physical fitness level, number of sites outside the lymph nodes involved, and whether blood LDH levels are elevated. More risk factors mean a lower expected response to standard treatment, which may prompt doctors to consider more aggressive approaches.
Five-year survival rates from the National Cancer Institute’s SEER database illustrate the range of outcomes. For cancer confined to a single region (stage I), about 80% of people survive at least five years. That drops to roughly 76% for stage II, 67% for stage III, and 56% for stage IV. Age also plays a significant role: people diagnosed before age 55 have an 80% five-year survival rate, while those 65 and older have a rate closer to 56%.
Standard Treatment
The backbone of DLBCL treatment is a chemotherapy combination called R-CHOP, which pairs a targeted antibody with four chemotherapy drugs and a steroid. The “R” stands for rituximab, an antibody that locks onto the CD20 protein found on the surface of the cancer cells, flagging them for destruction by the immune system. The remaining drugs work by damaging the cancer cells’ DNA and blocking their ability to divide.
A typical R-CHOP cycle is given every three weeks. Most patients receive six cycles, meaning treatment spans about four and a half months. Some people also receive radiation therapy to areas where the cancer was bulkiest. The addition of rituximab to this regimen was a major advance that significantly improved cure rates, and R-CHOP has remained the standard of care for over two decades.
When Standard Treatment Doesn’t Work
About one-third of patients either don’t respond fully to R-CHOP or relapse afterward. For these cases, the next step has traditionally been higher-dose chemotherapy followed by a stem cell transplant using the patient’s own cells.
A newer option is CAR-T cell therapy, in which a patient’s own immune cells are collected, genetically engineered in a lab to recognize and attack lymphoma cells, and then infused back into the body. CAR-T therapy is generally considered for patients whose cancer has come back after two or more lines of treatment, or who have relapsed after a stem cell transplant. Ideal candidates tend to be those with a relatively low tumor burden, normal LDH levels, slow disease growth, and good overall physical fitness. CAR-T has produced durable remissions in a meaningful number of patients who had no other options, though it can cause serious short-term side effects including high fevers and neurological symptoms as the engineered cells ramp up their attack.
Long-Term Side Effects of Treatment
Because DLBCL treatment is intensive, survivors face some long-term health risks worth knowing about. The two most significant late effects are heart problems and second cancers. One of the chemotherapy drugs in R-CHOP can weaken heart muscle over time, so doctors typically monitor heart function during and after treatment. People who received radiation to the chest have an increased risk of breast cancer, with screening generally starting 8 to 15 years after treatment, when that risk begins to rise.
Fatigue can linger for months after treatment ends. Nerve tingling or numbness in the hands and feet, a side effect of one of the chemotherapy drugs, sometimes persists long after the last cycle. Regular follow-up visits in the years after treatment are designed to catch these late effects early and manage them before they become serious problems.